Ortho

Quidel Corporation will buy New Jersey in-vitro diagnostic specialist Ortho Clinical for $6 billion in cash and newly issued shares, per a late December announcement from the San Diego-based company.

Expected to close in the first half of 2022, the deal will allow for “top-tier R&D capabilities, a more diverse product pipeline, and broader geographic footprint,” Quidel’s CEO said in the press release.

Mentions:

The state of the hunt:

Vaccine candidates from Novavax and J&J’s Janssen subsidiary entered Phase 3.
  Chinese regulators are reviewing inactivated vaccine candidates from CNBG for conditional authorization.
  Fujifilm’s flu drug Avigan (favipiravir) met its primary endpoint in a Phase 3 trial for treatment of Covid-19.

 

Vaccines

Phase 3 candidates:
 
China weighs approval of CNBG shots: State regulators are reviewing CNBG’s two…